Top

Published in:

01-03-2014 | Original

Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial

Authors: Jan J. De Waele, S. Carrette, M. Carlier, V. Stove, J. Boelens, G. Claeys, I. Leroux-Roels, E. Hoste, P. Depuydt, J. Decruyenaere, A. G. Verstraete

Published in: Intensive Care Medicine | Issue 3/2014

Abstract

Purpose

There is variability in the pharmacokinetics (PK) of antibiotics (AB) in critically ill patients. Therapeutic drug monitoring (TDM) could overcome this variability and increase PK target attainment. The objective of this study was to analyse the effect of a dose-adaption strategy based on daily TDM on target attainment.

Methods

This was a prospective, partially blinded, and randomised controlled trial in patients with normal kidney function treated with meropenem (MEM) or piperacillin/tazobactam (PTZ). The intervention group underwent daily TDM, with dose adjustment when necessary. The predefined PK/pharmacodynamic (PK/PD) target was 100 % fT_>4MIC [percentage of time during a dosing interval that the free (f) drug concentration exceeded 4 times the MIC]. The control group received conventional treatment. The primary endpoint was the proportion of patients that reached 100 % fT_>4MIC and 100 % fT_>MIC at 72 h.

Results

Forty-one patients (median age 56 years) were included in the study. Pneumonia was the primary infectious diagnosis. At baseline, 100 % fT_>4MIC was achieved in 21 % of the PTZ patients and in none of the MEM patients; 100 % fT_>MIC was achieved in 71 % of the PTZ patients and 46 % of the MEM patients. Of the patients in the intervention group, 76 % needed dose adaptation, and five required an additional increase. At 72 h, target attainment rates for 100 % fT_>4MIC and 100 % fT_>MIC were higher in the intervention group: 58 vs. 16 %, p = 0.007 and 95 vs. 68 %, p = 0.045, respectively.

Conclusions

Among critically ill patients with normal kidney function, a strategy of dose adaptation based on daily TDM led to an increase in PK/PD target attainment compared to conventional dosing.

Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, Investigators EIGo (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329PubMedCrossRef

Antonelli M, Bonten M, Cecconi M, Chastre J, Citerio G, Conti G, Curtis JR, Hedenstierna G, Joannidis M, Macrae D, Maggiore SM, Mancebo J, Mebazaa A, Preiser JC, Rocco P, Timsit JF, Wernerman J, Zhang H (2013) Year in review in Intensive Care Medicine 2012. II: pneumonia and infection, sepsis, coagulation, hemodynamics, cardiovascular and microcirculation, critical care organization, imaging, ethics and legal issues. Intensive Care Med 39:345–364PubMedCentralPubMedCrossRef

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228PubMedCrossRef

Pletz MW, Lipman J (2013) Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing. Intensive Care Med 39:1322–1324PubMedCrossRef

Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J (2009) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64:142–150PubMedCrossRef

Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J (2009) Piperacillin penetration into tissue of critically ill patients with sepsis–bolus versus continuous administration? Crit Care Med 37:926–933PubMedCrossRef

Aubert G, Carricajo A, Coudrot M, Guyomarc’h S, Auboyer C, Zeni F (2010) Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit 32:517–519PubMedCrossRef

Blondiaux N, Wallet F, Favory R, Onimus T, Nseir S, Courcol RJ, Durocher A, Roussel-Delvallez M (2010) Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 35:500–503PubMedCrossRef

Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Vincent JL, Wallemacq P, Jacobs F (2010) Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126PubMedCentralPubMedCrossRef

10.

Goncalves-Pereira J, Povoa P (2011) Antibiotics in critically ill patients—a systematic review of the pharmacokinetics of beta-Lactams. Crit Care 15:R206PubMedCentralPubMedCrossRef

11.

Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851 (quiz 859)PubMedCrossRef

12.

Shekar K, Fraser JF, Roberts JA (2013) Can optimal drug dosing during ECMO improve outcomes? Intensive Care Med 39:2237PubMedCrossRef

13.

Udy AA, Roberts JA, Lipman J (2013) Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 9:2070–2082

14.

Kromdijk W, Sikma MA, van den Broek MP, Beijnen JH, Huitema AD, de Lange DW (2013) Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique. [letter]. Intensive Care Med 39(5):977–978PubMedCrossRef

15.

Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J (2010) First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 35(2):156–163

16.

Carlier M, Carrette S, Roberts JA, Stove V, Verstraete AG, Hoste E, Decruyenaere J, Depuydt P, Lipman J, Wallis SC, De Waele JJ (2013) Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 17:R84PubMedCrossRef

17.

Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ (2013) Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56:272–282PubMedCrossRef

18.

Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J (2013) Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 56:236–244PubMedCrossRef

19.

Troger U, Drust A, Martens-Lobenhoffer J, Tanev I, Braun-Dullaeus RC, Bode-Boger SM (2012) Decreased meropenem levels in intensive care unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. Int J Antimicrob Agents 40:370–372PubMedCrossRef

20.

Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA (2012) Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30–39PubMedCrossRef

21.

Hayashi Y, Lipman J, Udy AA, Ng M, McWhinney B, Ungerer J, Lust K, Roberts JA (2013) beta-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents 41:162–166PubMedCrossRef

22.

Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J (2010) Augmented renal clearance in the intensive care unit: an illustrative case series. Int J Antimicrob Agents 35:606–608PubMedCrossRef

23.

Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F (2012) Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 56:2129–2131PubMedCentralPubMedCrossRef

24.

van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, Verhoef J, Bonten MJM (2005) Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Respir Crit Care Med 171:480–487PubMedCrossRef

25.

26.

Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D (2013) Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med 39:1247–1252PubMedCrossRef

27.

Roberts JA, Joynt GM, Choi GY, Gomersall CD, Lipman J (2012) How to optimise antimicrobial prescriptions in the intensive care unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 39:187–192PubMedCrossRef

28.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612PubMedCentralPubMedCrossRef

29.

Mouton JW, den Hollander JG (1994) Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38:931–936PubMedCentralPubMedCrossRef

30.

Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725–1730PubMedCentralPubMedCrossRef

31.

Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL (2002) Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50:425–428PubMedCrossRef

32.

Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332–339PubMedCrossRef

33.

Carlier M, Stove V, Roberts JA, Van de Velde E, De Waele JJ, Verstraete AG (2012) Quantification of seven beta-lactam antibiotics and two beta-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int J Antimicrob Agents 40:416–422

34.

Udy AA, Putt MT, Boots RJ, Lipman J (2011) ARC–augmented renal clearance. Curr Pharm Biotechnol 12:2020–2029PubMedCrossRef

35.

Hites M, Taccone FS, Wolff F, Cotton F, Beumier M, De Backer D, Roisin S, Lorent S, Surin R, Seyler L, Vincent JL, Jacobs F (2013) Case-control study of drug monitoring of beta-lactams in obese critically ill patients. Antimicrob Agents Chemother 57:708–715PubMedCentralPubMedCrossRef

36.

Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J (2011) The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 50:99–110PubMedCrossRef

37.

Roberts JA, Norris R, Paterson DL, Martin JH (2012) Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 73:27–36PubMedCentralPubMedCrossRef

38.

Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA (2012) Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2:35PubMedCentralPubMedCrossRef

39.

Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA (2012) Therapeutic drug monitoring of beta-lactam antibiotics in burns patients–a one-year prospective study. Ther Drug Monit 34:160–164PubMedCrossRef

Title: Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
Authors: Jan J. De Waele
S. Carrette
M. Carlier
V. Stove
J. Boelens
G. Claeys
I. Leroux-Roels
E. Hoste
P. Depuydt
J. Decruyenaere
A. G. Verstraete
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 3/2014
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-013-3187-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Regret

Contrast-enhanced ultrasonography for bedside imaging in subclinical acute kidney injury

Target mean arterial pressure after cardiac arrest

Clinical practice guideline on diagnosis and treatment of hyponatraemia

Year in review in Intensive Care Medicine 2013: II. Sedation, invasive and noninvasive ventilation, airways, ARDS, ECMO, family satisfaction, end-of-life care, organ donation, informed consent, safety, hematological issues in critically ill patients

What is the optimal post-arrest hemodynamic strategy? Towards personalized resuscitation strategies